IL-33 Expression Is Lower in Current Smokers at Both Transcriptomic and Protein Level.
Faiz, A
Mahbub, RM
Boedijono, FS
Tomassen, MI
Kooistra, W
Timens, W
Nawijn, M
Hansbro, PM
Johansen, MD
Pouwels, SD
Heijink, IH
Massip, F
de Biase, MS
Schwarz, RF
Adcock, IM
Chung, KF
van der Does, A
Hiemstra, PS
Goulaouic, H
Xing, H
Abdulai, R
de Rinaldis, E
Cunoosamy, D
Harel, S
Lederer, D
Nivens, MC
Wark, PA
Kerstjens, HAM
Hylkema, MN
Brandsma, C-A
van den Berge, M
Cambridge Lung Cancer Early Detection Programme,
- Publisher:
- American Thoracic Society
- Publication Type:
- Journal Article
- Citation:
- Am J Respir Crit Care Med, 2023
- Issue Date:
- 2023-09-14
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
faiz-et-al-2023-il-33-expression-is-lower-in-current-smokers-at-both-transcriptomic-and-protein-level.pdf | Accepted version | 4.16 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author |
Faiz, A |
|
dc.contributor.author | Mahbub, RM | |
dc.contributor.author | Boedijono, FS | |
dc.contributor.author | Tomassen, MI | |
dc.contributor.author | Kooistra, W | |
dc.contributor.author | Timens, W | |
dc.contributor.author | Nawijn, M | |
dc.contributor.author | Hansbro, PM | |
dc.contributor.author | Johansen, MD | |
dc.contributor.author | Pouwels, SD | |
dc.contributor.author | Heijink, IH | |
dc.contributor.author | Massip, F | |
dc.contributor.author | de Biase, MS | |
dc.contributor.author | Schwarz, RF | |
dc.contributor.author | Adcock, IM | |
dc.contributor.author | Chung, KF | |
dc.contributor.author | van der Does, A | |
dc.contributor.author | Hiemstra, PS | |
dc.contributor.author | Goulaouic, H | |
dc.contributor.author | Xing, H | |
dc.contributor.author | Abdulai, R | |
dc.contributor.author | de Rinaldis, E | |
dc.contributor.author | Cunoosamy, D | |
dc.contributor.author | Harel, S | |
dc.contributor.author | Lederer, D | |
dc.contributor.author | Nivens, MC | |
dc.contributor.author | Wark, PA | |
dc.contributor.author | Kerstjens, HAM | |
dc.contributor.author | Hylkema, MN | |
dc.contributor.author | Brandsma, C-A | |
dc.contributor.author | van den Berge, M | |
dc.contributor.author | Cambridge Lung Cancer Early Detection Programme, | |
dc.date.accessioned | 2023-09-28T01:04:41Z | |
dc.date.available | 2023-09-28T01:04:41Z | |
dc.date.issued | 2023-09-14 | |
dc.identifier.citation | Am J Respir Crit Care Med, 2023 | |
dc.identifier.issn | 1073-449X | |
dc.identifier.issn | 1535-4970 | |
dc.identifier.uri | http://hdl.handle.net/10453/172350 | |
dc.description.abstract | INTRODUCTION: IL-33 is a pro-inflammatory cytokine thought to play a role in the pathogenesis of asthma and COPD. A recent clinical trial using the anti-IL33 antibody showed a reduction in exacerbation and improved lung function in ex-smokers but not current smokers with COPD. In this study, we aimed to understand the effects of smoking status on IL-33. METHODS: We investigated the association of smoking status with the level of gene expression of IL33 in the airways in eight independent transcriptomic studies of lung airways. Additionally, we performed western blot and immunohistochemistry for IL-33 in lung tissue to assess protein levels. RESULTS: Across the bulk RNA-sequencing datasets, IL-33 gene expression and its signaling pathway were significantly lower in current- compared to ex- or never-smokers and increased upon smoking cessation (p<0.05). Single-cell sequencing showed that IL-33 is predominantly expressed in resting basal epithelial cells and decreases during the differentiation process triggered by smoke exposure. We also found a higher transitioning of this cellular sub-population into a more differentiated cell type during chronic smoking, potentially driving the reduction of IL-33. Protein analysis demonstrated lower IL-33 levels in lung tissue from COPD current- compared to ex-smokers and a lower proportion of IL-33 positive basal cells in current versus ex-smoking controls. CONCLUSION: We provide strong evidence that cigarette smoke leads to an overall reduction in IL33 expression in both transcriptomic and protein level and this may be due to the decrease in resting basal cells. Together, these findings may explain the clinical observation that a recent antibody-based anti-IL-33 treatment is more effective in ex- than current smokers with COPD. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | American Thoracic Society | |
dc.relation.ispartof | Am J Respir Crit Care Med | |
dc.relation.isbasedon | 10.1164/rccm.202210-1881OC | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | 11 Medical and Health Sciences | |
dc.subject.classification | Respiratory System | |
dc.subject.classification | 3201 Cardiovascular medicine and haematology | |
dc.subject.classification | 3202 Clinical sciences | |
dc.title | IL-33 Expression Is Lower in Current Smokers at Both Transcriptomic and Protein Level. | |
dc.type | Journal Article | |
utslib.location.activity | United States | |
utslib.for | 11 Medical and Health Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
pubs.organisational-group | /University of Technology Sydney/Strength - CFI - Centre for Inflammation | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2023-09-28T01:04:39Z | |
pubs.publication-status | Published online |
Abstract:
INTRODUCTION: IL-33 is a pro-inflammatory cytokine thought to play a role in the pathogenesis of asthma and COPD. A recent clinical trial using the anti-IL33 antibody showed a reduction in exacerbation and improved lung function in ex-smokers but not current smokers with COPD. In this study, we aimed to understand the effects of smoking status on IL-33. METHODS: We investigated the association of smoking status with the level of gene expression of IL33 in the airways in eight independent transcriptomic studies of lung airways. Additionally, we performed western blot and immunohistochemistry for IL-33 in lung tissue to assess protein levels. RESULTS: Across the bulk RNA-sequencing datasets, IL-33 gene expression and its signaling pathway were significantly lower in current- compared to ex- or never-smokers and increased upon smoking cessation (p<0.05). Single-cell sequencing showed that IL-33 is predominantly expressed in resting basal epithelial cells and decreases during the differentiation process triggered by smoke exposure. We also found a higher transitioning of this cellular sub-population into a more differentiated cell type during chronic smoking, potentially driving the reduction of IL-33. Protein analysis demonstrated lower IL-33 levels in lung tissue from COPD current- compared to ex-smokers and a lower proportion of IL-33 positive basal cells in current versus ex-smoking controls. CONCLUSION: We provide strong evidence that cigarette smoke leads to an overall reduction in IL33 expression in both transcriptomic and protein level and this may be due to the decrease in resting basal cells. Together, these findings may explain the clinical observation that a recent antibody-based anti-IL-33 treatment is more effective in ex- than current smokers with COPD. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph